Contineum Therapeutics CTNM Insider Ownership

Updated Oct 10, 2026

Across the past 12 months, open-market trades by Contineum Therapeutics insiders were all sales, totaling $1.85 million (122.3K shares).

• Behind Contineum Therapeutics' open-market sales in the past 12 months were 3 insiders, and no insider bought.
• Daniel S. Lorrain (Chief Scientific Officer) sold the most Contineum Therapeutics stock on the open market over the past 12 months, $1.13 million (76.03K shares), most recently on July 9, 2026.
• Carmine N. Stengone (CEO and President) made the most recent open-market trade by an insider of Contineum Therapeutics, a sale of 2.5K shares for $41,142 on September 8, 2026.
• Apart from open-market trades, CTNM insiders acquired 89.34K shares through option exercises and conversions in the past 12 months.
• According to Business Quant data, insiders at Contineum Therapeutics reported 174.18K shares in total in their latest Form 4 filings, unchanged from 174.18K shares at the end of Q2 2026.
• By type of ownership, CTNM insiders hold all of their 174.18K shares directly.
• CTNM's insider total is spread across 4 insiders who have filed a Form 4 in the past two years.
• Contineum Therapeutics' three biggest insider holders are Daniel S. Lorrain (Chief Scientific Officer, 135.2K shares), Carmine N. Stengone (CEO and President, 17.22K shares) and Stephen L. Huhn (CMO & Senior VP, Clinical Development, 12.8K shares), based on their latest Form 4 filings.
• Daniel S. Lorrain alone accounts for 77.62% of the shares held by Contineum Therapeutics insiders.
• Institutions held 81.21% of Contineum Therapeutics' outstanding shares in their Q2 2026 13F filings, insiders about 0.46% based on their latest Form 4 filings, and other investors, including the public, the remaining 18.33%.
• Over the past 12 months, 12 insiders reported transactions in Contineum Therapeutics stock in 33 Form 4 filings.
• These insider figures for Contineum Therapeutics are based on Form 4 filings through September 8, 2026.